Profile of T-cell lymphomas in Ibadan, Nigeria

Longitudinal Flow Decorrelations in Xe+Xe Collisions at sqrt[s_{NN}]=5.44 TeV with the ATLAS Detector.

Physical review letters·2021

Medium-Induced Modification of Z-Tagged Charged Particle Yields in Pb+Pb Collisions at 5.02 TeV with the ATLAS Detector.

Physical review letters·2021

Search for Heavy Resonances Decaying into a Photon and a Hadronically Decaying Higgs Boson in pp Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Physical review letters·2021

Search for Higgs Boson Decays into a Z Boson and a Light Hadronically Decaying Resonance Using 13 TeV pp Collision Data from the ATLAS Detector.

Physical review letters·2020

Dijet Resonance Search with Weak Supervision Using sqrt[s]=13 TeV pp Collisions in the ATLAS Detector.

Physical review letters·2020

CP Properties of Higgs Boson Interactions with Top Quarks in the tt[over ¯]H and tH Processes Using H→γγ with the ATLAS Detector.

Physical review letters·2020

Local therapy to recurrent/metastatic foci augments the benefit of immune checkpoint inhibitors in nasopharyngeal carcinoma.

European journal of cancer (Oxford, England : 1990)·2026

Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer.

European journal of cancer (Oxford, England : 1990)·2026

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?

European journal of cancer (Oxford, England : 1990)·2026

Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.

European journal of cancer (Oxford, England : 1990)·2026

Diagnostic pitfalls and unmet needs in neuroendocrine neoplasms: The added value of collegial expert pathology review through the national TENpath network.

European journal of cancer (Oxford, England : 1990)·2026

Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.

European journal of cancer (Oxford, England : 1990)·2026

IL-23 promotes PD-L1 expression and tumor immune evasion via METTL16 pathway.

American journal of cancer research·2026

Mechanism and intervention strategy of thymus atrophy in cancer immunotherapy.

American journal of cancer research·2026

Suspected recurrent sarcoma resembling feline injection-site sarcoma with spinal cord invasion in a cat.

JFMS open reports·2026

Disulfidptosis as an immunometabolic rheostat in gastrointestinal cancers: tuning the balance between T Cell exhaustion and immunogenic cell death.

Frontiers in cell and developmental biology·2026

Immune checkpoint inhibitors in thymic epithelial tumors: current evidence, immune-related toxicity, and perioperative considerations-a narrative review.

Journal of thoracic disease·2026

Molecularly guided management of pediatric endobronchial inflammatory myofibroblastic tumor: a report of two cases on surgical and targeted intervention.

Translational pediatrics·2026

Related Experiment Videos

Profile of T-cell lymphomas in Ibadan, Nigeria

Related Concept Videos

Longitudinal Flow Decorrelations in Xe+Xe Collisions at sqrt[s_{NN}]=5.44 TeV with the ATLAS Detector.

Medium-Induced Modification of Z-Tagged Charged Particle Yields in Pb+Pb Collisions at 5.02 TeV with the ATLAS Detector.

Search for Heavy Resonances Decaying into a Photon and a Hadronically Decaying Higgs Boson in pp Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Search for Higgs Boson Decays into a Z Boson and a Light Hadronically Decaying Resonance Using 13 TeV pp Collision Data from the ATLAS Detector.

Dijet Resonance Search with Weak Supervision Using sqrt[s]=13 TeV pp Collisions in the ATLAS Detector.

CP Properties of Higgs Boson Interactions with Top Quarks in the tt[over ¯]H and tH Processes Using H→γγ with the ATLAS Detector.

Local therapy to recurrent/metastatic foci augments the benefit of immune checkpoint inhibitors in nasopharyngeal carcinoma.

Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer.

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?

Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.

Diagnostic pitfalls and unmet needs in neuroendocrine neoplasms: The added value of collegial expert pathology review through the national TENpath network.

Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.

IL-23 promotes PD-L1 expression and tumor immune evasion via METTL16 pathway.

Mechanism and intervention strategy of thymus atrophy in cancer immunotherapy.

Suspected recurrent sarcoma resembling feline injection-site sarcoma with spinal cord invasion in a cat.

Disulfidptosis as an immunometabolic rheostat in gastrointestinal cancers: tuning the balance between T Cell exhaustion and immunogenic cell death.

Immune checkpoint inhibitors in thymic epithelial tumors: current evidence, immune-related toxicity, and perioperative considerations-a narrative review.

Molecularly guided management of pediatric endobronchial inflammatory myofibroblastic tumor: a report of two cases on surgical and targeted intervention.

Related Experiment Videos

Profile of T-cell lymphomas in Ibadan, Nigeria

Related Concept Videos

Related Articles